Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 28;217(12):e20190354. doi: 10.1084/jem.20190354

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Zhang et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 5. — The antitumoral effect of combinatorial IL17 and PD-1 blockade is CD8⁺ T cell dependent. (A) Flow cytometry–based analysis of tumor-infiltrating CD8⁺ and CD8⁺IFNγ⁺ cells. Tumors were obtained from syngeneic mice orthotopically implanted with KPC cells and treated with isotype IgG, aPD-1, aIL17/aIL17R, or aIL17/aIL17R/aPD-1 antibodies (n = 10 mice/group). Results are expressed as the percentage of total CD45⁺ gated viable cells. (B) IHC-based quantification of tumor-infiltrating cells expressing granzyme B (GzmB⁺) in tumors from A. Results are expressed as the total number of cells/mm². (C) Tumor volumes of orthotopically implanted KPC cells into WT syngeneic mice treated with isotype IgG, anti-IL17/IL17R/PD-1, or anti-CD8 antibodies (aCD8; n = 10). (D) Tumor volumes of orthotopically implanted KPC cells into CD8-deficient (CD8^−/−) syngeneic mice treated with isotype IgG or anti-IL17/IL17R/PD-1 antibodies (n = 6–7 mice/group). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.